Etiology and risk factors for severe indirect neonatal hyperbilirubinemia
DOI:
https://doi.org/10.5457/ams.v55i1.826Keywords:
etiology, risk factors, significant indirect hyperbilirubinemia, neonatesAbstract
Background: The aim of this study was to evaluate the etiology and risk factors for severe indirect hyperbilirubinemia in neonates treated at the tertiary level Pediatric Clinic, in a five-year period
Methods: A retrospective single-center, observational study included all consecutive neonates admitted at the tertiary level Pediatric Clinic, with a diagnosis of severe indirect hyperbilirubinemia. Relevant data from the anamnesis, clinical data, laboratory findings and types of treatment, were obtained from the Admission Protocols and electronic database of treated neonates. Statistical analysis applied standard methods, and the research was approved by the Ethics Committee of the institution.
Results: In a five-year period, 996 neonates with severe indirect hyperbilirubinemia were identified, which accounted for almost a third of all hospitalized neonates, and 6.85% of all live births. The most common perinatal risk factors were male gender (59.2%), prematurity (42.0%) and perinatal asphyxia (17.0%). In 13.5% of neonates, severe indirect hyperbilirubinemia had hemolytic causes. Sepsis (42.3%) and extravascular blood collections (47.2%) were significant causes, and the rarest cause of severe neonatal hyperbilirubinemia were hereditary metabolic disorders (0.4%). As part of the treatment, 24 of these neonates required exchange transfusion, and this study group significantly most often had isoimmunization as the cause, with significantly higher mean values of bilirubin, along with significantly lower values of hemoglobin, erythrocytes and hematocrit.
Conclusion: Hyperbilirubinemia is one of the most common clinical problems in neonatology, which remains a permanent challenge in terms of prevention, improvement of treatment and outcome.
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
